



# *EMGN – The Future of the Credit Guarantee Business*

*CERSA – SGRs Case Study*

# Our unique approach

We design financial instruments that share risks with our partners multiplying public resources and increasing the supply of finance


## Our resources

- European Commission
- European Investment Bank
- Local authorities & National Promotional Institutions
- Other investors\*

## Our approach

We design and deploy **financial instruments** that target funding gaps

## Our partners



## Small businesses



**5x leverage of public resources\*\***

\*Includes EIF's own resources and other external resources including private investors.

\*\*On aggregate based on 2020 transactions. Depending on the instrument and the transaction, the leverage achieved can range from 4x to 40x.

Source: EIF Annual Report 2020.

# Our main debt financing solutions

We share risk with our banking partners to encourage lending and improve lending terms to riskier small businesses


	<b>Capped guarantees</b>	<b>Uncapped guarantees</b>	<b>Credit enhancement (securitisation)</b>	<b>Private credit</b>
<b>Risk sharing mechanism</b>	AAA guarantee of losses up to a capped rate per loan (free of charge)	AAA guarantee of losses uncapped (guarantee fee)	Credit enhancement of securitized SME loan portfolios provides economic and regulatory relief for originators	Crowding in additional investors via cornerstone investments in direct lending funds
<b>Benefit for small businesses</b>	Loans at better terms (collateral reduction, maturity extension, lower interest rates)	Loans at better terms (collateral reduction, maturity extension, lower interest rates)	Increased lending to riskier small businesses	Bespoke debt packages, speedy deployment and flexible approach
<b>Net commitments</b>	€6.8bn	€29.2bn	€22.2bn	€5.2bn

Notes: Transaction level data based on net commitments (signatures), excludes capacity building investments and senior and subordinated loans under EaSI.

Source: SPA reporting, data as at 30/06/2021.

# True sale securitisation

- The reference portfolio is transferred by a legal true sale to an SPV, so the originator is not the lender of record of the loans any more.
- The SPV issues securitisation notes backed by the securitised portfolio.
- The notes are purchased by investors and the proceeds are captured by the originator. This structure is commonly used for funding purposes but it can be also used for capital relief.



# Synthetic securitisation (i)

## ■ Synthetic securitisation

- The originator remains to be the lender of record of all loans (there is no legal true sale) and the securitised exposures remain on the balance sheet of the originator.
- The credit risk of a pool of exposures is divided in tranches, with subordination among the tranches in the loss allocation.
- The risk is transferred by means of Credit Risk Mitigation.


## ■ Forms of Credit Risk Mitigation (CRM)

- CRM is a technique used **to reduce the credit risk** associated with exposures held by an institution:
  - “**unfunded credit protection**”
  - “**funded credit protection**”

# Synthetic securitisation (ii)

## ■ Synthetic securitisation via **Unfunded Credit Protection**

- Protection buyer (originator) obtains a contractual obligation of a counterparty to cover losses (e.g. bilateral guarantee)
- Protection buyer relies on credit quality of counterparty (ability to make required payments)
- Type of instrument: credit default swaps, financial guarantees
- Requires a counterparty with a low(er) risk weight (i.e. EIF/EIB: 0% risk weight)



# Synthetic securitisation (iii)

## ■ Synthetic securitisation via **Funded Credit Protection**

- Protection buyer (originator) obtains a contractual obligation of a counterparty to cover losses. It is a fully collateralised protection instrumented by the issuance of securitisation notes or also called credit-linked notes (CLNs) by an SPV
- Risk transfer does not depend on credit quality of counterparty/investor
- Type of instruments: credit-linked notes

